The complexities of Xpert® MTB/RIF interpretation

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 3, 2015, Pages 273-275

  Lippincott, C K ^a,b   Miller, M B ^a   Van Rie, A ^c   Weber, D J ^a   Sena, A C ^a   Stout, J E ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b RIGHT TO CARE   (South Africa)

^c University of North Carolina at Chapel Hill   (United States)

^d DUKE UNIVERSITY   (United States)

Author keywords

Hospital epidemiology; Infection control; Tuberculosis; United States

Indexed keywords

CAPREOMYCIN; ETHIONAMIDE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ADULT; AGED; ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM DETECTION; CASE REPORT; CAUSE OF DEATH; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DYSPNEA; FEMALE; FEVER; HUMAN; LUNG NODULE; LUNG TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; NIGHT SWEAT; NONHUMAN; PRIORITY JOURNAL; SPUTUM CYTODIAGNOSIS; THORAX RADIOGRAPHY; TUBERCULOSIS RAPID TEST; DRUG EFFECTS; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MICROBIOLOGY; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANCE; NUCLEIC ACID AMPLIFICATION; PROCEDURES; SERODIAGNOSIS; SPUTUM; STANDARDS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; UNITED STATES;

ADULT; AGED; ANTIBIOTICS, ANTITUBERCULAR; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HIV SERONEGATIVITY; HUMANS; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RIFAMPIN; SPECIMEN HANDLING; SPUTUM; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; UNITED STATES;

EID: 84923276016     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0432     Document Type: Article

References (10)

1. Steingart K R, Schiller I, Horne D J, et al. Xpertw MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014; (1): CD009593.
2. Food & Drug Administration. FDA permits marketing of first U.S. test labeled for simultaneous detection of tuberculosis bacteria and resistance to the antibiotic rifampin. Washinton DC, USA: FDA, 2013. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm362602.htm. Accessed November 2014.
3. Centers for Disease Control and Prevention. Availability of an assay for detecting Mycobacterium tuberculosis, Including rifampin-resistant strains, and considerations for its use- United States, 2013. MMWR Morb Mortal Wkly Rep 2013; 62: 821-824.
4. World Health Organization. Xpertw MTB/RIF implementation manual: technical and operational 'how-to'; practical considerations. WHO/HTM/TB/2014.1. Geneva, Switzerland: WHO, 2014.
5. World Health Organization. Global tuberculosis report, 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland: WHO, 2013.
6. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2012. Atlanta, GA, USA: US Department of Health and Human Services, CDC, 2013.
7. Foundation for Innovative New Diagnostics. Performance of Xpert MTB/RIF Version G4 assay. Geneva, Switzerland: FIND, 2011. http://www.stoptb.org/wg/gli/assets/documents/map/findg4cartridge.pdf. Accessed November 2014.
8. Williamson D A, Roberts S A, Bower J E, et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2012; 16: 216-220.
9. Rigouts L, Gumusboga M, de Rijk W B, et al. Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations. J Clin Microbiol 2013; 51: 2641-2645.
10. Boyles T H, Hughes J, Cox V, et al. False-positive Xpertw MTB/RIF assays in previously treated patients: need for caution in interpreting results. Int J Tuberc Lung Dis 2014; 18: 876-878.